DDrare: Database of Drug Development for Rare Diseases

Suvorexant (DrugBank: Suvorexant)

3 diseases

ID	Disease name (Link within this page)	Number of trials
5	Progressive supranuclear palsy	1
6	Parkinson disease	1
13	Multiple sclerosis/Neuromyelitis optica	1

5. Progressive supranuclear palsy [ 82 clinical trials, 107 drugs, (DrugBank: 36 drugs), 60 drug target genes, 90 drug target pathways]

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 82 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04014387 (ClinicalTrials.gov)	June 2, 2019	11/4/2019	Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)	Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)	Treatment	Drug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsule	University of California, San Francisco	US Department of Veterans Affairs	Recruiting	18 Years	N/A	All	60	Phase 4	United States

6. Parkinson disease [ 2,123 clinical trials, 2,046 drugs, (DrugBank: 324 drugs), 183 drug target genes, 198 drug target pathways]

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,123 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02729714 (ClinicalTrials.gov)	April 2016	26/1/2016	A Pilot Study of Suvorexant for Insomnia in Parkinson Disease	A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease	Insomnia	Drug: Suvorexant;Drug: Placebo	Burdick, Daniel, M.D.	Merck Sharp & Dohme Corp.	Recruiting	30 Years	80 Years	All	20	Phase 4	United States

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03110315 (ClinicalTrials.gov)	March 28, 2017	28/3/2017	A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia	A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia	Multiple Sclerosis;Fatigue;Insomnia	Drug: Suvorexant;Drug: Placebo	Theodore R. Brown, MD MPH	Merck Sharp & Dohme Corp.	Recruiting	18 Years	75 Years	All	30	Phase 4	United States